Mersana and Teva in USD 334 M deal for preclinical cancer drug
By Debbie Tranter
Pharma Deals Review: Vol 2010 Issue 4 (Table of Contents)
Published: 25 May-2010
DOI: 10.3833/pdr.v2010.i4.1332 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Teva Pharmaceutical Industries has entered into an agreement with Mersana Therapeutics for rights to develop and commercialize XMT-1107 for the treatment of all indications, including cancer
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS